迪哲医药-U
(688192)
| 流通市值：52.26亿 | | | 总市值：176.49亿 |
| 流通股本：1.23亿 | | | 总股本：4.16亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 81,318,560 | 91,288,640 | 40,102,400 | 0 |
| 营业收入 | 81,318,560 | 91,288,640 | 40,102,400 | 0 |
| 二、营业总成本 | 338,128,124.1 | 1,252,634,286.09 | 896,482,852.81 | 536,264,657.75 |
| 营业成本 | 2,056,668.49 | 3,214,752.42 | 1,711,556.29 | - |
| 税金及附加 | 242,983.15 | 844,643.71 | 559,295.57 | 341,772.73 |
| 销售费用 | 91,500,983.93 | 210,050,481.42 | 135,784,195.29 | 76,311,179.99 |
| 管理费用 | 35,707,360.54 | 227,495,530.18 | 178,089,059.53 | 116,706,896.61 |
| 研发费用 | 204,770,425.91 | 805,598,483.2 | 578,964,914.76 | 343,437,904.5 |
| 财务费用 | 3,849,702.08 | 5,430,395.16 | 1,373,831.37 | -533,096.08 |
| 其中:利息费用 | 4,249,007.04 | 7,573,965.92 | 4,492,829.98 | 2,224,784.9 |
| 其中:利息收入 | -621,155.8 | 3,641,418.98 | 2,871,114.53 | 2,247,222.47 |
| 加:公允价值变动收益 | 3,833,744.82 | 22,518,778.81 | 18,310,623.89 | 13,056,410.21 |
| 资产处置收益 | - | -8,403.41 | -8,403.41 | -2,991.01 |
| 信用减值损失(新) | 31,113.23 | -395,986.23 | - | - |
| 其他收益 | 28,709,815.18 | 31,619,326.34 | 9,162,206.14 | 9,011,700.99 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -224,234,890.87 | -1,107,611,930.58 | -828,916,026.19 | -514,199,537.56 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -224,234,890.87 | -1,107,611,930.58 | -828,916,026.19 | -514,199,537.56 |
| 减:所得税费用 | - | 101,322.68 | 33,565.02 | 53,063.95 |
| 六、净利润 | -224,234,890.87 | -1,107,713,253.26 | -828,949,591.21 | -514,252,601.51 |
| 持续经营净利润 | -224,234,890.87 | -1,107,713,253.26 | -828,949,591.21 | -514,252,601.51 |
| 归属于母公司股东的净利润 | -224,234,890.87 | -1,107,713,253.26 | -828,949,591.21 | -514,252,601.51 |
| (一)基本每股收益 | -0.54 | -2.72 | -2.03 | -1.26 |
| (二)稀释每股收益 | -0.54 | -2.72 | -2.03 | -1.26 |
| 九、综合收益总额 | -224,234,890.87 | -1,107,713,253.26 | -828,949,591.21 | -514,252,601.51 |
| 归属于母公司股东的综合收益总额 | -224,234,890.87 | -1,107,713,253.26 | -828,949,591.21 | -514,252,601.51 |
| 公告日期 | 2024-04-30 | 2024-04-30 | 2023-10-28 | 2023-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |